tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

ALX Oncology price target lowered to $2 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on ALX Oncology (ALXO) to $2 from $5 and keeps a Buy rating on the shares. The company announced its decision to discontinue the development of evorpacept in gastric and gastroesophageal cancers based on the FDA’s feedback, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1